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LocomotionSensitization is a common feature of psychostimulants and sensitization effects are generally considered to be linked
to the addictive properties of these drugs. We used a conventional paired/unpaired Pavlovian protocol to induce a
context speciﬁc sensitization to the locomotor stimulant effect of a high dose of apomorphine (2.0 mg/kg). Twodays
following a 5 session sensitization inductionphase, a brief 5 minnon-drug test for conditioningwas conducted. Only
the paired groups exhibited locomotor stimulant conditioned response effects. Immediately following this brief test
for conditioning, the paired and the unpaired groups received injections of 0.05 mg/kg apomorphine, 2.0 mg/kg
apomorphine or vehicle designed to differentially impact memory re-consolidation of the conditioning. Two days
later, all groups received a sensitization challenge test with 2.0 mg/kg apomorphine. The 2.0 mg/kg apomorphine
post-trial treatment potentiated sensitization while the 0.05 mg/kg eliminated sensitization. These effects were
only observed in the paired groups. The activation of dopaminergic systems by the high dose of apomorphine
strengthened the drug/environment association whereas the inhibition of dopamine activity by the low auto-
receptor dose eliminated this association. The results point to the importance of conditioning to context speciﬁc
sensitization and targeting memory re-consolidation of conditioning as a paradigm to modify sensitization.vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Psychoactive drugs can have complex effects upon behavior that can
vary substantially for a particular drug depending upon dose, context
and prior history. Even when drug dose and environmental context are
held constant, the behavioral impact of a drug can change markedly
with repeated exposure to the same drug dose treatment. For a number
of psychostimulant drugs, particularly drugs with high drug abuse
liability such as cocaine and amphetamine, a positive behavioral
feedback occurs. With repeated intermittent psychostimulant drug
treatments, the magnitude of the behavioral response elicited by the
drug typically increases; and, in a non-drug test, the behavioral response
is increased in the same direction as the drug response. This behavioral
sensitization drug effect has been repeatedly demonstrated (Borowski
and Kuhn, 1991; Heidbreder and Shippenberg, 1994; Mattingly et al.,
1994; Carey and Gui, 1998; Bloise et al., 2007; Braga et al., 2009a,b; Dias
et al., 2010; Filip et al., 2010; Matos et al., 2010) and is generally
considered an important contributor to the addictive potency of
psychostimulant drugs such as cocaine (e.g., Robinson and Berridge,1993; Carey and Damianopoulos, 2006). Thus, it would appear that
psychostimulant behavioral sensitization effects are a composite of the
conditioned effects plus an increased unconditioned drug response
(Peris et al., 1990; Pert et al., 1990;Henry andWhite, 1991; Zeigler et al.,
1991; Kalivas et al., 1992; Robinson and Berridge, 1993; Jodogne et al.,
1994; Carey et al., 2005a; Braga et al., 2009a,b; Dias et al., 2010). The
quantitative contribution of Pavlovian conditioned drug effects to
behavioral sensitization, nonetheless, remains rather obscure (Einat
et al., 1996). Often but certainly not always the behavioral sensitization
effects are context speciﬁc (Einat et al., 1996) and this link to associated
test environment stimuli is sometimes the only basis for implicating
Pavlovian conditioning mechanisms to sensitization effects. Clearly,
however, context speciﬁcity links sensitization to an associative process
as the same protocol that induces sensitization effects also generates
Pavlovian conditioned drug responses to the contextual stimuli.
In Pavlovian conditioned drug effects, the conditioned response
occurs in the presence of the conditioned stimuli with the absence of
drug treatment. In contrast, for sensitization, both the drug treatment
and conditioned stimuli are present. Carey and co-workers (2005b)
alongwith others (e.g., Murray and Bevins, 2007) have pointed out that
drug treatments such as cocaine provide drug stimuli that can
contribute to the contextual stimulus complex. This latter consideration
is pertinent to the issue of the contribution of Pavlovian conditioned
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contextual stimuli were critical to the induction of sensitization effects,
then the conditioned response could simply be eliminated or substan-
tially attenuated by extinction resulting in elimination or diminution of
the sensitization effect. Extinction of a cocaine conditioned response,
however, has little or no impact upon the cocaine sensitization response
(Carey and Gui, 1998). While this result would seemingly, discount the
relevance of Pavlovian conditioned stimuli to sensitization effects, it is
also long known from animal conditioning studies that Pavlovian
conditioning is a primitive involuntary learning process that, as shown
in other areas of study (e.g., fear conditioning), is long lasting and highly
resistant to extinction (Pavlov, 1928). That is, the behavioral expression
of the conditioned response may be suppressed by an extinction
protocol but, nonetheless, it canbe reinstated either spontaneously after
a period of non-testing or by disinhibition with stress or other highly
arousing stimuli (Pavlov, 1928). Thus, when a drug sensitization test is
administered after an extinction protocol, the drug treatment could
disinhibit the extinction either by the introduction of the activatingdrug
effects or by the drug generated interoceptive stimuli. This type of
disinhibition is akin to the “priming” effect in instrumental conditioning
wherein an extinguished drug self-administration response is
reinstated by administering the drug prior to a non-drug or non-
reinforced test series. In this case, the “priming” effect of the drug
treatment can be seen as a disinhibition of extinction by drug induced
activation effects and/or by the introduction of drug stimuli which had
been present during the drug self-administration.
The relevant observation here is that extinction of the expression of
the conditioning in a non-drug test is not a sufﬁcient basis for
discounting the contribution of the Pavlovian conditioned stimuli to
the sensitization effect. Rather, the lack of impact of an extinction
procedure on sensitization is consistent with the fact that extinction is
an ineffective procedure for inducing enduring changes in cue reactivity
in drug addiction to achieve effective elimination of drug craving, drug
taking or relapse.
Recently Carey and co-workers (2008) reconceptualized Pavlovian
conditioning from a CS–CR formulation to a CS–memory trace–CR (CS–
MT–CR) process framework formulation. Importantly, recent studies
which have pointed to a new perspective regarding the plasticity of an
established memory trace suggest that viewing the CS as activating a
memory trace that is expressed as the CR, can offer an alternative
strategy to diminish or eliminate the CS–CR. Previously, a brief dynamic
phase in the formation of a memory trace was thought to exist only
during the formation of a new memory trace and only then could an
intervention prevent or enhance memory formation. This understand-
ing of the consolidation aspect ofmemoryhas been recognized for some
time (Duncan, 1949;McGaugh, 1966) in a variety of learning paradigms
in which manipulations ranging from electroconvulsive shock (ECS)
(Duncan, 1949), protein synthesis inhibitors (Flood et al., 1973; Flood
et al., 1975; Davis and Squire, 1984; Litvin andAnokhin, 2000; Lattal and
Abel, 2004; Gold, 2006) to glucose (Messier, 2004; Salinas and Gold,
2005) administeredduring a short post-trial temporal interval canblock
or enhance the retention of a learned response. In contrast, these same
treatments administered after a longer temporal interval (e.g. 2 h), have
no effect upon retention of the learning experience. Thus, a period of
memory vulnerability followed by invulnerability has led to a general
consensus that, following a brief post-trial time interval, memory traces
become consolidated and incorporated into the physical structure of the
brain. Recent analyses of memory, nonetheless, have suggested that the
memory trace is not hardwired; but, memory traces, each time they are
reactivated, once again become labile and sensitive to modiﬁcation
(Przybyzlawski and Sara, 1997; Nader et al., 2000; Berman and Dudai,
2001; Eisenberg et al., 2003; Nader, 2003; Pedeira and Maldonado,
2003; Dubiec et al., 2002; Dudai, 2004; McGaugh, 2004; Eisenhardt and
Menzel, 2007). This alternative conceptualization creates the possibility
that an establishedmemory can be re-activated by cue re-exposure and
then modiﬁed. This viewpoint of the memory trace differs from theperspective in which the original memory trace persists even alongside
new memory traces that compete with the expression of the original
memory trace. In fact, recent studies have shown that post-trial amnesic
treatments that follow shortly after non-drug re-exposure of animals
to cues associated with cocaine can impair the drug memory traces
(Lee et al., 2006).
Apomorphine behavioral stimulant effects are initiated by increases
in dopamine D1 and D2 receptor activities widely in the brain.
Seemingly, with repeated high dose apomorphine treatments there is
awidespreaddopaminergic activation in thehippocampus and cortex in
the presence of contextual stimuli and this association is strengthened
and reinforced by the concurrent increased activation of dopaminergic
reward areas in the brain (Robledo et al., 1992). This increase in
dopamine post-synaptic activity evoked by apomorphine paired to
contextual stimuli may facilitate the mnemonic system to enable
apomorphine treatments to forge potent and lasting associational
effects to contextual cues. In the present study we administer a high
dose of apomorphine (2.0 mg/kg) to induce behavioral sensitization to
the locomotor stimulant effects of the apomorphine treatment.
Subsequently we conduct a brief (5 min.) non-drug test to evoke the
conditioned apomorphine locomotor stimulant response and thereby
activate the memory trace of the association between the test
environment and apomorphine. Immediately after this re-consolidation
trial we administer treatments to inhibit/enhance dopaminergic
activity. Conveniently, apomorphine can also be used to serve this
purpose. Apomorphine at high dose levels (N0.5 mg/kg) activates
dopamine post-synaptic receptors and functions as a behavioral
stimulant but, at low doses (b0.1 mg/kg) apomorphine preferentially
is an agonist at dopamineD2autoreceptors and inhibitsDAneurons and
suppresses locomotor behavior. Accordingly, we administer either low
(0.05 mg/kg) or high (2.0 mg/kg) apomorphine treatments immedi-
ately after a brief conditioning trial so that thepost-trial drug treatments
occur at a time when the memory trace is being re-consolidated and
therefore vulnerable to modiﬁcation. Subsequent to this post-trial
treatment protocol we assess its impact on the previously established
apomorphine sensitization in a challenge test. The present report details
the results of the investigation.
2. Materials and methods
2.1. Subjects
Male Wistar albino rats provided by the State University of North
Fluminense, initially weighing 200–300 g were housed in individual
plastic cages (25×18×17 cm) until the end of experiment. Food and
waterwere freely available at all times. The vivariumwasmaintained at
a constant temperature (22+2 °C), and a 12/12 h light/dark cycle
(lights onat0700 handoff at 1900 h). All experimentoccurred between
8:00 and 15:00 h. For 7 days prior to all experimental procedures each
animal was weighed and handled daily for 5 min. All experiments were
conducted in strict accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals.
2.2. Apparatus and measurement of behavior
The behavioral measurements were conducted in a black open ﬁeld
chamber (60×60×45 cm). A closed-circuit video-camera (SONY,
model IR575M), mounted 60 cm above the arena was used to record
behavioral data. Locomotion, measured as distance traveled (m), was
automatically analyzed by EthoVision (Noldus, The Netherlands). The
complete test procedure was conducted automatically without the
presenceof the experimenter in the test room.All behavioral testingwas
conducted under dim red light to avoid the possible aversive quality of
white light and to enhance the contrast between the white subject and
dark background of the test chamber. The testing under red light
conditions is less stressful and also favors locomotor activation as the
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light of the testing room (Nasello et al., 1998). Masking noise was
provided by a fan located in the experimental room that was turned on
immediately prior to placing the animal in the experimental arena and
turned off upon removal of the animal from the experimental arena
(i.e., test chamber).
2.3. Drugs
Apomorphine–HCl (Sigma, St. Louis,MO, USA)was dissolved in 0.1%
ascorbate/saline (2.0 mg/ml) and was injected subcutaneously in the
nape of the neck at a dose of 2.0 and 0.05 mg/kg. A 0.1% ascorbate/saline
solutionwasused asvehicle for theapomorphineexperiments. All doses
were administered in a volumeof 1.0 ml/kgbodyweight. Drug solutions
were freshly prepared before each experiment.
2.4. Experimental procedure
The experiments were conducted following an experimental
protocol from Braga et al. (2009a, 2009b). First, all rats received three
30 min habituation sessions (habituation phase), conducted on
consecutive days. The habituation protocol was conducted so that a
stable baseline of the locomotor behavior could be established prior to
the start of the drug treatments. The animals were administered with
saline and placed in the experimental arena and locomotor activity was
measured. On the next day, the animals were assigned to groups
equated on baselines and were submitted to the pharmacological
treatment phase, in which there were three basic treatment groups: a
paired group, an unpaired group and a vehicle treatment group. In the
pairedgroup, rats received2.0 mg/kgapomorphine(APO-2.0-P; n=20)
immediately before being placed into the test environment and vehicle
administration 30 min after removal from the test environment. In the
unpaired group (APO-2.0-UP; n=20), rats received vehicle immedi-
ately before being placed into the test environment and apomorphine
2.0 mg/kg 30 min after being removed from the test environment. The
vehicle group (VEH; n=26) was treated in the same way as the paired
group except that the animals received vehicle prior to being placed in
the experimental arena. These treatments were administered for 5
consecutive days, one trial per day and served as the induction phase in
which locomotion was recorded for 30 min. The induction phase was
designed to establish anapomorphine sensitization response selectively
in the paired apomorphine treatment groups. After a period of 2 days
without injections or behavioral testing (withdrawal period), there was
a conditioning test in which the animals received an injection of saline
prior to being placed into the test environment and locomotion was
recorded for 5 min. Immediately after the 5 minute conditioning test,
the animals received their re-consolidation pharmacological treatment.
For that, thepaired, unpairedandvehicle groupsweredivided into three
subgroups in which one subgroup received 2.0 mg/kg apomorphine,
another subgroup received 0.05 mg/kg apomorphine and the otherTable 1
Treatment design for experiments.
Initial groups Induction phase Conditioning trial Reconsolidation tre
Arena Home
VEH (n=26) VEH VEH SAL VEH
APO-0.05
APO-2.0
VEH
APO-2.0-UP (n=20) VEH APO-2.0 SAL VEH
APO-0.05
APO-2.0
APO-2.0-P (n=20) APO-2.0 VEH SAL VEH
APO-0.05
APO-2.0
APO-2.0=apomorphine 2.0 mg/kg; APO-0.05=apomorphine 0.05 mg/kg; VEH = vehicle;subgroup received vehicle. Two days later, there was a sensitization
challenge test, in which the paired and unpaired groups received
2.0 mg/kg apomorphine. The experimental groups were categorized
in terms of 3 treatments: (a) their induction treatment, (b) their re-
consolidation treatment and (c) their drug treatment in the 2.0 mg/kg
apomorphine challenge test. The three APO paired (P) subgroupswere:
APO-2.0+APO-2.0+APO-2.0, (n=7); APO-2.0+APO-0.05+APO-2.0,
(n=6) and APO-2.0+VEH+APO-2.0, (n=7). The three APO unpaired
(UP) subgroups were: APO-2.0-UP+APO-2.0+APO-2.0, (n=7); APO-
2.0-UP+APO-0.05+APO-2.0, (n=6) and APO-2.0-UP+VEH+APO-
2.0, (n=7). The four vehicle (VEH) subgroups were: VEH+APO-2.0+
VEH, (n=7); VEH+APO-0.05+VEH, (n=6); VEH+VEH+VEH,
(n=7) and VEH+VEH+APO-2.0; (n=6). The treatment protocols
are summarized and presented in Table 1.
2.5. Statistics
In the induction phase, a repeated two-way analysis of variance
(ANOVA) was used to analyze the locomotor data to determine the
group effect, day effect, as well as the interactions between variables.
When a signiﬁcant effect of group versus day interaction was recorded,
datawere further analyzed by one-wayANOVA followed by the Duncan
post-hoc test (pb0.05) as the criterion for statistical signiﬁcance. The
behavioral data obtained from the conditioning test and sensitization
test were analyzed using a one-way ANOVA.Wherever indicated by the
ANOVA (group effectswith p-values b0.05), possible differences among
groups were analyzed by Duncan's multiple range test.
3. Results
Prior to the start of experimentation, the animals underwent a
three-day habituation procedure. The statistical analyses using a
one-way ANOVA indicated a signiﬁcant decrease in locomotion over
days [F (2, 195)=198.50; pb0.01] as expected for the development of
habituation to a novel environment (Cerbone and Sadile, 1994).
Duncan's test showed that day 1 had higher locomotor activity than
day 2 and day 3 (pb0.05) (data not shown) and day 2 had higher
locomotor activity than day 3 (pb0.05) (data not shown). Importantly,
prior to the initiation of the conditioning protocol, there were no
differences among the treatment groups (pN0.05) in any experiment.
Fig. 1 shows the results of the induction treatment phase where
separate groups received either vehicle or apomorphine (2.0 mg/kg)
paired/unpaired for 5 consecutive days. A repeated two-way ANOVA of
the vehicle/apomorphine drug treatment showed an interaction of
group×days [F (16, 244)=27.72; pb0.01], an effect of groups
[F (4, 61)=63.14; pb0.01] and an effect of days of treatment
[F (4, 244)=94.03; pb0.01]. A one-way ANOVA followed by Duncan's
multiple range test to further analyze the interaction of group×days,
showed that from days 1–5, the APO-2.0-P groups (i.e., APO-2.0-P+
VEH+APO-2.0, APO-2.0-P+APO-0.05+APO-2.0 and APO-2.0-P+atment Sensitization challenge test Final groups
VEH VEH+VEH+VEH (n=7)
VEH VEH+APO-0.05+VEH (n=6)
VEH VEH+APO-2.0+VEH (n=7)
APO-2.0 VEH+VEH+APO-2.0 (n=6)
APO-2.0 APO-2.0-UP+VEH+APO-2.0 (n=7)
APO-2.0 APO-2.0-UP+APO-0.05+APO-2.0 (n=6)
APO-2.0 APO-2.0-UP+APO-2.0+APO-2.0 (n=7)
APO-2.0 APO-2.0-P+VEH+APO-2.0 (n=7)
APO-2.0 APO-2.0-P+APO-0.05+APO-2.0 (n=6)
APO-2.0 APO-2.0-P+APO-2.0+APO-2.0 (n=7)
UP = unpaired; P = paired.
Fig. 2.Means and S. E. M. of effects of locomotor activity during the 5 min conditioning test.
* denotes higher locomotor activity for the APO-2.0-P groups than the VEH and APO-2.0-UP
groups (pb0.05; ANOVA followed by Duncan's multiple range test). The inset presents the
same data on a different scale more in line with the low level of locomotion in the 5min
non-drug test.
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APO-2.0-UP groups (pb0.05). Pertinent to the issue of development of
locomotor sensitization, an analysis (one-way ANOVA followed by
Duncan's test) carried out for the APO-2.0-P groups across the days of
administration showed higher locomotor activity on days 5 and 4 than
day 1 (pb0.05).
Fig. 2 presents the locomotor activity scores for the vehicle, APO-2.0-
unpaired andAPO-2.0-pairedgroups during the5 min conditioning test.
A one-way ANOVA showed that there was a difference among the
experimental groups [F (2, 63)=70.0; pb0.01] and the Duncan's test
showed that the APO-2.0-P group had higher locomotor levels than all
other groups (pb0.05).
Fig. 3 presents the locomotor activity scores for groups during the
sensitization test. A one-wayANOVAshowed that therewas a difference
among the experimental groups [F (9, 56)=19.51; pb0.01] and the
Duncan's test showed that the APO-2.0-P+APO-2.0+APO-2.0 group
had higher locomotor levels than all groups (pb0.05). The APO-2.0-P+
VEH+APO-2.0 showed higher locomotion than all the other groups
(pb0.05), except the APO-2.0-P+APO-2.0+APO-2.0 group.
4. Discussion
In the present study the high dose apomorphine treatment reliably
induced a behavioral sensitization effect expressed as hyper-locomotion.
This phenomenon has been demonstrated previously in a number of
publications (Damianopoulos and Carey, 1993; Mattingly et al., 1997;
Busidan andDow-Edwards, 1999; Bloise et al., 2007; Braga et al., 2009a,b;
Dias et al., 2010; Matos et al., 2010). While the role of conditioning and
context speciﬁcity is not always evident in apomorphine sensitization
studies (Damianopoulos and Carey, 1994; Mattingly et al., 1988) in the
present study a paired/unpaired Pavlovian conditioning protocol was
used so that our ﬁnding of sensitization and conditioned apomorphine
effects selectively in the paired groups indicated that the effects were
context speciﬁc and that associational processes were crucial for the
effects. In the brief 5 min non-drug conditioning test the paired
apomorphine group was the only group that exhibited a conditioned
locomotor stimulant effect. This result is a prerequisite condition for
the post-trial treatments to have a potential effect upon memory
re-consolidation. In this brief 5 min test the conditioned response effect
was robust statistically but yet there was only a very small fraction of the
apomorphine sensitization response. The key feature of this conditioned
effect liesnot in themagnitudeof the conditioned responsebut rather that
it is a behavioral manifestation of the activation of the memory trace by
the test environment cues of the high dose apomorphine association to
the test environment. The impact on sensitization of the post-trialFig. 1. Means and S. E. M. of effects of administration of apomorphine of 2.0 mg/kg on
locomotion during the induction phase. * denotes higher locomotor activity than the other
groups. # denotes higher locomotor activity on the 4th and 5th days than the 1st day for
the APO-2.0-P groups (pb0.05; ANOVA followed by Duncan's multiple range test).treatments was assessed in a subsequent high dose apomorphine
sensitization challenge test. In this challenge test the sensitization effects
were found selectively in the paired groups and there were prominent
bidirectional effects of the post-trial treatments. The dopamine activating
high dose apomorphine post-trial treatment resulted in a potentiation of
sensitization in the challenge test whereas, the dopamine inhibitory low
dose apomorphine post-trial treatment eliminated sensitization in the
challenge test. Consistent with a memory based interpretation of the
post-trial treatments was the ﬁnding that neither of these post-trial
treatments given to the unpaired groups had an effect on the challenge
test. Thisﬁnding is in linewith the fact that the post-trial treatmentswere
in fact unpaired treatments and therefore not linked to the test
environmentcues. Fromamemoryre-consolidationperspectivehowever,
the post-trial treatment drug effects occurred during the transient
re-consolidation of the memory trace activated by placement in the test
environment. The selectivity of the post-trial treatments to the paired
groups is consistent with the proposition that these post-trial treatments
impacted memory re-consolidation and enhanced and inhibited,
respectively the associational bond between the test environment and
the high dose apomorphine hyper-locomotion sensitization effect.Fig. 3. Means and S. E. M. of effects of administration of 2.0 mg/kg apomorphine on
locomotion during the sensitization test. ** denotes higher locomotor activity than all the
other groups. *denotes higher locomotor activity than all the other groups, except the APO-
2.0-P+APO-2.0+APO-2.0 group (pb0.05; ANOVA followed by Duncan's multiple range
test). IP = induction phase; RT = re-consolidation treatment; ST = sensitization test; U =
unpaired; P = paired; 2.0=apomorphine 2.0 mg/kg; 0.05=apomorphine 0.05 mg/kg.
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altogether surprising that present results implicate dopamine in the
re-consolidation process for this speciﬁc paradigm. Whether the post-
trial apomorphine treatments can impact re-consolidation processes
more broadly, however, necessitate the application of these treatments
to sensitization effects induced by drugs other than apomorphine
including dopaminergic as well as non-dopaminergic drugs that can
induce sensitization and conditioned effects. A key element in the
present study is that the lowdose apomorphine treatment that reversed
the psychostimulant sensitization was administered after a brief
exposure to the contextual stimuli. Consequently, such a reversal
treatment (i.e. low dose apomorphine) does not entail further exposure
to the high dose apomorphine treatment. This feature of a drugmemory
re-consolidation paradigm that does not entail further exposure to the
psychostimulant drug treatment that induced sensitization is clearly
desired in a therapeutic clinical setting. Furthermore, a drug treatment
such as a low dose of apomorphine given in a post-trial memory
re-consolidation paradigm is short acting and can be given episodically
and not chronically. While apomorphine at a high dose reliably can
induce sensitization and conditioning effects in rodent behavior it is not
considered an addictive drug for humans. Accordingly, it will be
important to evaluate the strategy employed in the present study
using psychostimulant drugs with high addictive potential such as
cocaine to induce conditioned and sensitization effects and then to
determine if inhibition of dopamine activity immediately after a brief
re-consolidation trial with a low dose of apomorphine can also reverse
sensitization effects induced by highly addictive psychostimulant drugs
such as cocaine. By directing the experimental attention to the
associational component of sensitization not only are sensitization
drug effects addressed but in addition so is cue activated craving.
Sensitization is a common feature of psychostimulant drugs such as
amphetamine and cocaine and it has been generally thought that this
sensitization effect is related to the addictive properties of these drugs
(e.g. Stewart and Badiani, 1993; Morgan et al., 2006). Indeed, the
neuroadaptive changes underlying sensitization are thought to resem-
ble those responsible for addiction. Therefore, an understanding of the
mechanisms of sensitization is of importance in that such information
could facilitate the development of improved treatments for addiction.
The occurrence of sensitization has been attributed to a variety of
neurobiological and behavioral factors such as accumulation of drug
metabolites, increases and/or decreases in drug affected receptors,
and habituation to contextual cues and associative conditioning to
environmental cues (Stewart and Vezina, 1991; Stewart and Badiani,
1993; Mattingly et al., 1997; Heyne and Wolffgramm, 1998; Tirelli
and Heidbreder, 1999; Zavala et al., 2000; Crombag et al., 2001;
Anagnostaras et al., 2002; Tirelli et al., 2005; Uslaner et al., 2006). Given
the critical importance of context speciﬁcity to sensitization effects,
associative processes need to be incorporated into any account of
sensitization. In that a typical sensitization protocol is essentially a
Pavlovian drug conditioning protocol, it is not surprising that the
contextual cues can acquire conditioned stimulus properties and in a
non-drug test evoke a conditioned drug response. The occurrence of a
conditioned drug response not only provides a positive link of the
associative connection between the drug treatment and the environ-
mental context in which the drug is experienced but it also provides
an opportunity to experimentally interact with the associative bond in
the absence of the psychostimulant drug treatment. Guided by this
formulation, we suggest that the approach employed in the present
study offers a new paradigm to modify sensitization effects for
conditioned and sensitized drug response to a psychostimulant drug
with well-deﬁned neurotransmitter mechanisms that is, conducting a
brief non-drug test to evoke the conditioned drug response and then
immediately following this brief exposure to the contextual cues by
administration of a post-trial drug treatment that is inhibitory in
relation to the neurotransmitters activated by the psychostimulant
drug. In the present study an autoreceptor preferring low dose ofapomorphine was used to suppress dopaminergic activity in conjunc-
tion with the re-consolidation of the conditioned association between
the high dose apomorphine treatment and the test environment. This
needs to be differentiated from a counter-conditioning protocol
wherein the drug treatment (e.g. a low dose of apomorphine) is given
before placement in the test environment. In fact, a counter-condition-
ing procedure using a low dose of apomorphine does not attenuate a
sensitized apomorphine locomotor stimulant response (Braga et al.,
2009b).
The post-trial strategy could readily be applied to psychostimulant
drugs with high addictive potential such as cocaine. In the case of
cocaine, the post-trial drug treatments to be administered after a brief
exposure to the conditioned cocaine cues would be the ones that
activate dopamine and/or serotonin autoreceptors to suppress activity
in these respective neuronal transmitter systems contemporaneously
with memory trace activation by the contextual cues. In this way, the
neurotransmitter systems that initiate and maintain the drug memory
trace will be inactivated and consequently the linkage of these
neurotransmitter systems to the contextual cues potentially can be
reversed and eliminated. Application of this novel approach to the
associational effects induced by addictive drugs offers the possibility of
the development of behavioral and pharmaceutical tools to address
critical treatment resistant issues such as craving and relapse. Clearly,
drug development that fails to address the associational dimension can
only be a behavioral masking pharmaceutical treatment requiring
chronic dosing. On the other hand, interfering with the drug
associational effects that are so critical to craving and relapse using
well-established memory disruptive manipulations such as protein
synthesis inhibitors does not have a clinical utility. In thepresent study a
strategy was employed that was directed at the associational compo-
nent of sensitization using a pharmaceutical with a well-delineated
mechanism of action that does not alter memory processes generally
but rather can be targeted to a speciﬁc association.
Clearly, this approach is only of relevance and applicable in drug
sensitization circumstances wherein a drug environment association is
manifested in a non-drug test inwhich the conditioned drug response is
elicited by environmental cues. It is the evocation of the conditioned
drug response that creates the crucial opportunity to apply post-trial
treatments that can interact with and modify the drug/environment
memory re-consolidation. This post-trial approach is not applicable
when the sensitization drug is administered during sensitization
induction since the association is not being re-consolidated or if the
sensitization protocol does not generate a conditioned drug response to
non-drug cues. In that major treatment issues in drug abuse involve
activation of drug like reactions and craving by non-drug cues the
post-trial strategy may have substantial clinical signiﬁcance.
Acknowledgments
This research was supported by UENF and FAPERJ, L. W. M. is a
recipient of a fellowship from UENF-Brazil, F.R.C.D. is a recipient of a
fellowship from FAPERJ-Brazil and M.P.C. is a CNPq research fellow.We
thank Gina Nunes Teixeira for technical assistance and Dr. Richard Ian
Samuels for revision of the text.
References
Anagnostaras SG, Schallert T, Robinson TE. Memory processes governing amphetamine-
induced psychomotor sensitization. Neuropsychopharmacology 2002;26:703–15.
Berman DE, Dudai Y. Memory extinction, learning anew and learning the new:
dissociations in the molecular machinery of learning in cortex. Science 2001;292:
2417–9.
BloiseE, Carey RJ, CarreraMP. Behavioral sensitization produced bya single administration
of apomorphine: implications for the role of Pavlovian conditioning in the mediation
of context-speciﬁc sensitization. Pharmacol Biochem Behav 2007;86:449–57.
Borowski B, Kuhn CM. Chronic cocaine administration sensitizes behavioral but no
neuroendocrine responses. Brain Res 1991;543:301–6.
Braga PQ, Dias FR, Carey RJ, Carrera MP. Low dose apomorphine induces context-speciﬁc
sensitization of hypolocomotion without conditioning: support for a new state
34 M.P. Carrera et al. / Pharmacology, Biochemistry and Behavior 99 (2011) 29–34dependent retrieval hypothesis of drug conditioning and sensitization. Pharmacol
Biochem Behav 2009a;93:128–33.
Braga PQ, Dias FR, Carey RJ, Carrera MP. Behavioral sensitization to dopaminergic
inhibitory and stimulatory effects induced by low vs. high dose apomorphine
treatments: an unconventional dose and response reversal sensitization challenge
test reveals sensitization mechanisms. Behav Brain Res 2009b;204:169–74.
Busidan Y, Dow-Edwards DL. Behavioral sensitization to apomorphine in adult rats
exposed to cocaine during the preweaning period: a preliminary study. Pharmacol
Biochem Behav 1999;63:417–21.
Carey RJ, Damianopoulos EN. Cocaine conditioning and sensitization: the habituation
factor. Pharmacol Biochem Behav 2006;84:128–33.
Carey RJ, Gui J. Cocaine conditioning and cocaine sensitization: what is the
relationship? Behav Brain Res 1998;92:67–76.
Carey RJ, DePalma G, Damianopoulos E. Acute and chronic cocaine behavioral effects in
novel versus familiar environments: open-ﬁeld familiarity differentiates cocaine
locomotor stimulant effects from cocaine emotional behavioral effects. Behav Brain
Res 2005a;158:321–30.
Carey RJ, DePalma G, Damianopoulos E, Shanahan A. Stimulus gated cocaine sensitization:
interoceptivedrug cue control of cocaine locomotor sensitization. Pharmacol Biochem
Behav 2005b;82:353–60.
Carey RJ, Damianopoulos EN, Shanahan AB. Cocaine conditioned behavior: a cocaine
memory trace or an anti-habituation effect. Pharmacol Biochem Behav 2008;90:
625–31.
Cerbone A, Sadile AG. Behavioral habituation to spatial novelty: interference and
noninterference studies. Neurosci Biobehav Rev 1994;18:497–518.
Crombag HS, Badiani A, Chan J, Dell'Orco J, Dineen SP, Robinson TE. The ability of
environmental context to facilitate psychomotor sensitization to amphetamine can
be dissociated from its effect on acute drug responsiveness and on conditioned
responding. Neuropsychopharmacology 2001;24:680–90.
Damianopoulos EN, Carey RJ. Apomorphine sensitization effects: evidence for environ-
mentally contingent behavioral reorganization processes. Pharmacol Biochem Behav
1993;45:655–63.
Damianopoulos EN, Carey RJ. A new method to assess Pavlovian conditioning of
psychostimulant drug effects. J Neurosci Methods 1994;53:7-17.
Davis HP, Squire LR. Protein synthesis and memory: a review. Psychol Bull 1984;96:
518–59.
Dias FR, Carey RJ, Carrera MP. Apomorphine-induced context speciﬁc behavioural
sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and
uncoupled from contextual cues by the D2 antagonist sulpiride. Psychopharmacology
2010;209:137–51.
Dubiec J, LeDoux JL, Nader K. Cellular and systems reconsolidation in the hippocampus.
Neuron 2002;36:527–38.
Dudai Y. The neurobiology of reconsolidation, or, how stable is the engram? Annu Rev
Psychol 2004;55:51–86.
Duncan CP. The retroactive effect of electro sock on learning. J Comp Physiol Psychol
1949;42:33–44.
Einat H, Einat B, Allen M, Talangbayan H, Tsafnat T, Szechtman H. Associational and
non-associational mechanisms in locomotor sensitization to the dopamine agonist
quinpirole. Psychopharmacology 1996;127:95-101.
Eisenberg M, Kobilo T, Berman TE, Dudai Y. Stability of retrieved memory: inverse
correlation with trace dominance. Science 2003;301:1102–4.
Eisenhardt D, Menzel R. Extinction learning, reconsolidation and internal reinforcement
hypothesis. Neurobiol Learn Mem 2007;87:167–73.
Filip M, Alenina N, Bader M, Przegalinski E. Behavioral evidence for the signiﬁcance of
serotonin (5-HT) receptors in cocaine addiction. Addict Biol 2010;15:227–49.
Flood JF, Rosenzweig MR, Benne EL, Orme AB. The inﬂuence of duration of protein
synthesis inhibition on memory. Physiol Behav 1973;10:555–62.
Flood JF, Bennet EL, Orme AE, Rosenzweig MR. Effects of protein synthesis inhibition on
memory for active avoidance training. Physiol Behav 1975;14:177–84.
Gold PE. The many faces of amnesia. Learn Mem 2006;13:506–14.
Heidbreder CA, Shippenberg TS. U-69593 prevents cocaine sensitization by normalizing
basal accumbens dopamine. Neuroreport 1994;5:1797–800.
Henry DJ, White FJ. Repeated cocaine administration causes persistent enhancement of
D1 dopamine receptor sensitivity within the rat nucleus accumbens. J Pharmacol
Exp Ther 1991;258:882–90.
Heyne A, Wolffgramm J. The development of addiction to d-amphetamine in an animal
model: same principles as for alcohol and opiates. Psychopharmacology 1998;140:
510–8.
Jodogne C, Marinelli M, Le Moal M, Piazza PV. Animals predisposed to develop
amphetamine self-administration show higher susceptibility to develop contextualconditioning of both amphetamine-induced hyperlocomotion and sensitization.
Brain Res 1994;657:236–44.
Kalivas PW, Striplin CD, Steketee JD, Klitenick MA, Duffy P. Cellular mechanisms of be-
havioral sensitization to drugs of abuse (Review). Ann NY Acad Sci 1992;654:128–35.
Lattal KM, Abel T. Behavioral impairments caused by injections of protein synthesis
inhibitor anisomyacin after contextual retrieval reverse with time. Proc Natl Acad
Sci USA 2004;101:4667–72.
Lee JLC, Milton AL, Everitt BJ. Cue-induced cocaine seeking and relapse are reduced by
disruption of drug memory reconsolidation. J Neurosci 2006;26:881–7.
Litvin OO, Anokhin KV. Mechanisms of memory reorganization during retrieval of
acquired behavior in chicks: the effects of protein synthesis inhibition in the brain.
Neurosci Behav Physiol 2000;30:671–8.
Matos LW, Carey RJ, Carrera MP. Apomorphine conditioning and sensitization: the
paired/unpaired treatment order as a new major determinant of drug conditioned
and sensitization effects. Pharmacol Biochem Behav 2010;96:317–24.
Mattingly BA, Gotsick JE, Salamanca K. Latent sensitization to apomorphine following
repeated low doses. Behav Neurosci 1988;102:553–8.
Mattingly BA, Hart TC, Lim K, Perkins C. Selective antagonism of dopamine D1 and D2
receptors does not block the development of behavioral sensitization to cocaine.
Psychopharmacology 1994;114:239–42.
Mattingly BA, Koch C, Osborne FH, Gotsick JE. Stimulus and response factors affecting
the development of behavioral sensitization to apomorphine. Psychopharmacology
1997;130:109–16.
McGaugh JL. Time dependent processes in memory storage. Science 1966;153:1351–8.
McGaugh J. Memory reconsolidation hypothesis revived but restrained: theoretical
comment on Biedenkupp and Rudy. Behav Neurosci 2004;118:1140–2.
Messier C. Glucose improvement of memory: a review. Eur J Pharmacol 2004;490:33–7.
MorganD, Liu Y, Roberts DC. Rapid and persistent sensitization to the reinforcing effects of
cocaine. Neuropsychopharmacology 2006;31:121–8.
Murray JE, BevinsRA. Behavioral andneuropharmacological characterizationof nicotine as
a conditioned stimulus. Eur J Pharmacol 2007;56:91-104.
Nader K. Memory traces unbound. Trends Neurosci 2003;26:65–72.
Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala
for reconsolidation after retrieval. Nature 2000;406:722–6.
Nasello AG, Machado C, Bastos JF, Felicio LF. Sudden darkness induces a high activity-low
anxiety state in male and female rats. Physiol Behav 1998;63:451–4.
Pavlov IP. Lectures on conditioned reﬂexes. New York: International; 1928.
Pedeira ME, Maldonado H. Protein synthesis subserves reconsolidation or extinction
depending on reminder duration. Neuron 2003;38:863–9.
Peris J, Boyson SJ, Cass WA, Curella P, Dwoskin LP, Larson G, et al. Persistence of
neurochemical changes in dopamine systems after repeated cocaine administration.
J Pharmacol Exp Ther 1990;253:38–44.
Pert A, Post RM, Weiss SRB. Conditioning as a critical determinant of sensitization
induced by psychomotor stimulants. NIDA Res Monogra 1990;97:208–41.
Przybyzlawski J, Sara SJ. Reconsolidation of memory after its reactivation. Behav Brain
Res 1997;84:241–6.
Robinson CE, Berridge KC. The neural basis of drug craving: an incentive-sensitization
theory of addiction. Brain Res Rev 1993;18:247–91.
Robledo P, Maldonado-Lopez R, Koob GF. Role of dopamine receptors in the nucleus
accumbens in the rewardingproperties of cocaine.AnnNYAcadSci 1992;654:509–12.
Salinas JA, Gold PE. Glucose regulation of memory for reward reduction in young and
aged rats. Neurobiol Aging 2005;26:45–52.
Stewart J, Badiani A. Tolerance and sensitization to the behavioral effects of drugs.
Behav Pharmacol 1993;42:89-312.
Stewart J, Vezina P. Extinction procedures abolish conditioned stimulus control but
spare sensitized responding to apomorphine. Behav Pharmacol 1991;2:65–71.
Tirelli E, Heidbreder C. Conditioning of and contextual sensitization to apomorphine-
induced climbing in mice: evidence against the habituation hypothesis. Behav
Neurosci 1999;113:368–76.
Tirelli E, Michel A, Brabant C. Cocaine-conditioned activity persists for a longer time than
cocaine-sensitized activity in mice: implications for the theories using Pavlovian
excitatory conditioning to explain the context-speciﬁcity of sensitization. Behav Brain
Res 2005;165:18–25.
Uslaner JM, Acerbo MJ, Jones SA, Robinson TE. The attribution of incentive salience to a
stimulus that signals an intravenous injection of cocaine. Behav Brain Res 2006;16:
320–4.
Zavala AR, Nazarian A, Crawford CA, McDougall SA. Cocaine-induced behavioral
sensitization in the young rat. Psychopharmacology 2000;151:291–8.
Zeigler S, Lipton J, TogaA, EllisonG.Continuouscocaine administrationproducespersisting
changes in brain neurochemistry and behavior. Brain Res 1991;552:27–35.
